Rapt Therapeutics $RAPT is Medicxi Ventures Management Jersey Ltd's 4th Largest Position

Key Points

• Medicxi Ventures Management Jersey Ltd reduced its stake in Rapt Therapeutics by 87.5%, selling over 19 million shares and now holding approximately 2.8 million shares, which represents about 5.2% of its portfolio.
• Brokerage ratings for Rapt Therapeutics are mixed, with one analyst giving it a strong-buy rating while the average analyst rating stands at "Moderate Buy" with a consensus price target of $21.57.
• Rapt Therapeutics reported a loss of ($0.65) EPS for the last quarter, falling short of analysts' expectations and is projected to have an EPS of -2.14 for the current fiscal year.

Medicxi Ventures Management Jersey Ltd cut its holdings in shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) by 87.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,794,000 shares of the company's stock after selling 19,558,000 shares during the period. Rapt Therapeutics makes up about 5.2% of Medicxi Ventures Management Jersey Ltd's portfolio, making the stock its 4th largest holding. Medicxi Ventures Management Jersey Ltd owned 16.89% of Rapt Therapeutics worth $22,352,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Checkpoint Capital L.P. purchased a new position in Rapt Therapeutics in the 1st quarter valued at about $134,000. AQR Capital Management LLC purchased a new position in Rapt Therapeutics in the 1st quarter valued at about $188,000. ADAR1 Capital Management LLC lifted its stake in Rapt Therapeutics by 408.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock valued at $7,284,000 after buying an additional 4,796,455 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in Rapt Therapeutics by 303.1% in the 1st quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock valued at $6,116,000 after buying an additional 3,769,414 shares in the last quarter. Finally, Comerica Bank lifted its stake in Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RAPT has been the topic of a number of research reports. Zacks Research lowered shares of Rapt Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 22nd. UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the stock a "neutral" rating in a research note on Tuesday, August 12th. Wells Fargo & Company reissued an "overweight" rating and issued a $38.00 target price (down from $51.00) on shares of Rapt Therapeutics in a research note on Friday, August 8th. Wall Street Zen raised shares of Rapt Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, HC Wainwright raised their target price on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research note on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.57.

Rapt Therapeutics Stock Performance

Shares of NASDAQ:RAPT traded up $0.21 during trading on Tuesday, hitting $17.63. The company's stock had a trading volume of 144,394 shares, compared to its average volume of 82,396. The business has a 50 day moving average price of $11.65 and a two-hundred day moving average price of $9.35. The company has a market capitalization of $291.60 million, a PE ratio of -1.24 and a beta of -0.10. Rapt Therapeutics has a fifty-two week low of $5.67 and a fifty-two week high of $26.56.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.04). As a group, equities analysts expect that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.